The 46 most recent market catalysts affecting $MRNA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 75
Why is Moderna (MRNA) Stock Trending After Hours?
Moderna (MRNA) shares are trending and saw a significant jump in the regular session, continuing into after-hours, due to the announcement that three abstracts on its investigation…
Sep 21, 2026
Macro/Central Bank
Neutral
Impact 65
'White House Drafting Executive Order To Take Over NIH Grant Approvals' - The Hill
The White House is reportedly drafting an executive order that would give it more oversight of the NIH's grant approval process. This is significant because the NIH is a primary so…
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 75
Moderna shares are trading higher. The company announced three abstracts on its mRNA-based individualized neoantigen therapy intismeran autogene have been accepted for presentation at the ESMO Congress 2026.
This news is a significant positive catalyst for Moderna. The acceptance of abstracts for a major medical conference like ESMO 2026 indicates that their individualized neoantigen t…
Sep 21, 2026
Market Technicals
Neutral
Impact 65
10 Health Care Stocks Whale Activity In Today’s Session
The filing highlights unusual options activity, often indicative of large investors ('whales') taking significant positions. This matters because such activity can precede notable …
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 55
Moderna To Present Three Abstracts On Intismeran Autogene At European Society For Medical Oncology Congress 2026
Moderna announced the acceptance of three abstracts for presentation at the European Society for Medical Oncology (ESMO) Congress in October 2026. These abstracts concern intismera…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 92
Moderna Stock Is Surging: What's Going On?
Moderna's stock has surged over 100% in the past month, primarily due to the announcement on August 19th of successful Phase 3 results for its individualized cancer vaccine, intism…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 85
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
Moderna's stock experienced a massive surge, more than doubling in a month, after announcing positive Phase 3 results for its personalized mRNA cancer vaccine in melanoma, develope…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 75
Moderna shares are trading lower after Rothschild & Co downgraded the stock from Neutral to Sell.
The downgrade by Rothschild & Co from Neutral to Sell is a significant negative catalyst for Moderna. Analyst downgrades, especially from a 'Neutral' to 'Sell' rating, often signal…
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 65
Moderna Stock Moves Lower Wednesday: What's Going On?
Moderna's stock is seeing a dip following a substantial 170% surge over the past month. This pullback is attributed to traders balancing recent positive news, such as a landmark on…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 75
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
This filing highlights the significant positive Phase 3 results for Moderna and Merck's personalized mRNA cancer vaccine, a major breakthrough as the first mRNA-based cancer therap…
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 65
This Moderna Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
The filing highlights analyst upgrades for three distinct companies, with Moderna (MRNA) being the primary focus. Argus Research upgraded MRNA from Hold to Buy and set a $180 price…
Aug 28, 2026
Corporate Catalyst
Bearish
Impact 75
Moderna shares are trading lower after the company announced the pricing of its upsized $2.6 billion offering of Convertible Senior Notes.
The pricing of a $2.6 billion upsized convertible senior notes offering by Moderna is a significant corporate catalyst. While convertible notes offer a lower interest rate than tra…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
Moderna Says FDA Approved sBLAs For 2026-2027 Spikevax And mNEXSPIKE Formulas Targeting JN.1-Lineage XFG Subvariant; Says Vaccines Expected Available In Coming Days
Moderna's FDA approval for its updated Spikevax and mNEXSPIKE formulas targeting the JN.1-lineage XFG subvariant is a significant positive for the company, securing its position fo…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 65
Moderna Borrows $2 Billion To Expand Oncology Business
Moderna is strategically raising $2 billion through convertible senior notes to bolster its oncology business, a move that follows promising Phase 3 trial results for its individua…
Aug 27, 2026
Corporate Catalyst
Bearish
Impact 85
Moderna shares are trading lower after the company announced a proposed $2 billion offering of convertible senior notes.
The announcement of a $2 billion convertible senior notes offering by Moderna is a significant corporate catalyst. Convertible notes can lead to dilution if converted into equity, …
Aug 26, 2026
Corporate Catalyst
Bearish
Impact 65
Moderna Stock Dips Wednesday: What's Going On?
Moderna's stock is experiencing a modest pullback, attributed to routine profit-taking and consolidation, after a substantial 150% surge. This surge was driven by landmark Phase 3 …
Aug 25, 2026
Market Technicals
Bullish
Impact 55
Moderna Shares Rise Over 5% After Key Trading Signal
The filing details a 'Power Inflow' alert for Moderna (MRNA) on August 25th, indicating a strong trend of buying activity from both institutional and retail investors. This proprie…
Aug 25, 2026
Market Technicals
Neutral
Impact 55
10 Health Care Stocks Whale Activity In Today’s Session
The filing highlights 'whale' options activity, which refers to large-volume trades by institutional or high-net-worth investors. This activity can signal potential future price mo…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Moderna shares are trading higher after Wolfe Research upgraded its rating on the stock from Underperform to Peer Perform.
This upgrade from 'Underperform' to 'Peer Perform' by Wolfe Research indicates a shift in analyst perception regarding Moderna's valuation or future prospects. While not a 'Buy' ra…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 55
Wolfe Research Upgrades Moderna to Peer Perform
Wolfe Research upgraded Moderna's rating from Underperform to Peer Perform, signaling a more neutral to slightly positive stance on the stock. This matters as analyst ratings can i…
Aug 24, 2026
Corporate Catalyst
Bearish
Impact 75
Moderna Stock Slides Monday Following Historic Rally: What's Going On?
Moderna (MRNA) shares are experiencing a pullback on Monday after a historic rally last week. The rally was triggered by the announcement of positive Phase 3 trial results for its …
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 75
MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week
The filing details the specific events that drove retail investor interest in several stocks. Moderna's successful late-stage cancer vaccine trial with Merck is a major catalyst, d…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 85
Moderna shares are trading higher. The stock may be rallying on this week's announcement that topline results from the Phase 3 INTerpath-001 trial met its primary and a key secondary endpoint.
The positive Phase 3 trial results for INTerpath-001 represent a major corporate catalyst for Moderna. This success validates their research and development efforts, potentially le…
Aug 21, 2026
Market Technicals
Bullish
Impact 55
JP Morgan Maintains Underweight on Moderna, Raises Price Target to $77
JP Morgan analyst Jessica Fye maintained an 'Underweight' rating on Moderna, signaling continued caution regarding the company's long-term prospects or competitive landscape. Howev…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 85
COVID-19 Made Moderna Famous: Cancer Could Define Its Future
Moderna, which saw its revenue and stock price decline significantly post-COVID-19 vaccine demand, has announced a major breakthrough in its personalized mRNA cancer vaccine in par…
Aug 20, 2026
Corporate Catalyst
Bearish
Impact 85
QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History
Moderna (MRNA) experienced a dramatic 25% stock drop, eyeing its worst day, immediately following a record 177% surge. The initial spike was due to groundbreaking positive Phase 3 …
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 85
Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst
Moderna (MRNA) and Merck (MRK) announced highly positive interim Phase 3 data for their individualized cancer therapy, intismeran, in combination with Keytruda, for advanced skin c…
Aug 20, 2026
Corporate Catalyst
Bearish
Impact 95
Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’
Moderna (MRNA) experienced a massive 177% stock surge after announcing positive Phase 3 trial results for its personalized mRNA cancer vaccine, developed in partnership with Merck …
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 75
Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)
Moderna and Merck announced a significant medical breakthrough with positive Phase 3 results for an individualized mRNA cancer vaccine, the first successful late-stage trial of its…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $89
Morgan Stanley analyst Terence Flynn maintained an 'Equal-Weight' rating on Moderna (MRNA) but substantially raised the price target from $39 to $89. This action indicates that whi…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 95
Moderna, Webull, Bitmine Immersion, Strategy and Merck: Why These 5 Stocks Are on Investors' Radars Today
Moderna and Merck experienced massive stock rallies due to the successful Phase 3 trial of their mRNA-based personalized cancer vaccine for melanoma. This is a game-changer for Mod…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 75
Trump Adds to Wealth With Moderna Stock Gains: Here’s How Much President Made
Moderna's stock experienced a massive surge due to the successful Phase 3 trial results for its personalized mRNA cancer vaccine, a significant milestone for mRNA technology in onc…
Aug 19, 2026
Macro/Central Bank
Bearish
Impact 85
Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today
The U.S. Treasury's intervention to double long-dated debt buybacks was the primary driver of market movements, aiming to reduce benchmark yields and provide liquidity. This action…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 85
Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.
The positive clinical trial results for intismeran autogene with KEYTRUDA represent a major validation for mRNA technology in cancer treatment, specifically for melanoma. This succ…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 85
Investors Should Position For Humanoid Robot Boom—Here's A Picks-And-Shovels Play; First mRNA Cancer Vaccine Succeeds
The filing highlights two major market-moving events. First, Moderna and Merck's successful Phase 3 trial for an mRNA cancer vaccine represents a significant validation of Moderna'…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 85
Moderna shares are trading higher after the company and Merck announced topline results from the Phase 3 INTerpath-001 trial met its primary and a key secondary endpoint.
This headline represents a significant corporate catalyst for Moderna and Merck. The successful Phase 3 trial for their personalized mRNA cancer vaccine validates the mRNA platform…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine
Moderna has secured FDA approval for its seasonal flu vaccine, mFLUSIVA, for adults 50 years and older. This is a crucial development as it diversifies Moderna's revenue streams be…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Moderna shares are trading higher after the company announced FDA approval for mFLUSIVA.
The FDA approval of mFLUSIVA is a significant positive catalyst for Moderna, validating its mRNA platform beyond COVID-19 and opening up a new revenue stream in the influenza vacci…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Moderna's mFLUSIVA Wins FDA Approval As First mRNA-Based Flu Vaccine For Adults 50 And Older
This FDA approval is a significant positive for Moderna, validating its mRNA platform beyond COVID-19 and opening up a new, lucrative market segment. The first-mover advantage in t…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 65
Moderna Advances Ebola Vaccine Into Human Testing
Moderna's initiation of a Phase 1 clinical trial for an Ebola vaccine is a positive development, signaling progress in diversifying its infectious disease pipeline beyond COVID-19.…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 85
Moderna shares are trading lower after the company announced that its norovirus vaccine candidate, mRNA-1403, did not meet Phase 3 success criteria and it is preparing to enrol an additional cohort.
This is a significant negative catalyst for Moderna (MRNA) as a key pipeline candidate, mRNA-1403, failed to meet its primary endpoint in Phase 3. This directly impacts the company…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 75
Moderna Q2 EPS $(1.97) Beats $(2.10) Estimate, Sales $145.000M Beat $102.998M Estimate
Moderna's substantial beat on both EPS and sales is a strong positive signal for the company, indicating effective cost management and/or higher-than-expected demand for its produc…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.